Back to Journals » Cancer Management and Research » Volume 11

Competing Morbidities In Advanced Head And Neck Squamous Cell Carcinoma Concurrent Chemoradiotherapy: A Strong Implication Of A Multidisciplinary Team Approach

Authors Lazzari G, De Cillis MA, Buccoliero G, Silvano G

Received 2 September 2019

Accepted for publication 22 October 2019

Published 18 November 2019 Volume 2019:11 Pages 9771—9782

DOI https://doi.org/10.2147/CMAR.S229524

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo


Grazia Lazzari,1 Maria Assunta De Cillis,2 Giovanni Buccoliero,3 Giovanni Silvano1

1Radiation Oncology Unit, S. Giuseppe Moscati Hospital, Taranto 74100, Italy; 2Otorynolaringoiatry Unit, S. Giuseppe Moscati Hospital, Taranto 74100, Italy; 3Infection Diseases Unit, S. Giuseppe Moscati Hospital, Taranto 74100, Italy

Correspondence: Grazia Lazzari
Radiation Oncology Unit, S. Giuseppe Moscati Hospital, Str. Per Martina Franca, Taranto 74100, Italy
Tel +039-099 4585721
Email lazzarigrazia@gmail.com

Abstract: Concurrent chemoradiotherapy (CCRT) is the standard approach for the treatment of locally advanced head and neck squamous cell carcinoma. Despite its undisputed advantages, CCRT is associated with acute and late toxicities, leading to unfavorable implications (eg, unplanned interruptions and noncancer-related mortality). The former prolongs the overall treatment time leading to a detrimental effect on tumor control. The latter consists of several noncancer morbidities arising from treatment-related toxicities, identifying a new pathway in cancer fate. This pathway has been termed noncancer mortality or competing mortality and consists of a series of treatment-competing morbidities, which nullify all therapeutic efforts aimed at curing these patients. The management of patients with head and neck squamous cell carcinoma who experience treatment-related toxicities is complex and requires expertise in oncological treatment as well as supportive care. The optimal management of these patients should start with knowledge regarding the most important competing morbidities developing during all phases of the disease (ie, from diagnosis to follow-up) to minimize treatment interruptions, ensure appropriate psychological support, and achieve the best oncological result. The purpose of the present review is to analyze the most important competing morbidities due to patient’s condition at baseline and CCRT, which could result in noncancer mortality. A multidisciplinary team approach is strongly required in the management of this disease.

Keywords: competing mortality, head and neck squamous cell carcinoma, concurrent chemoradiotherapy, multidisciplinary team
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]